Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients.
The occurrence of neuroleptic malignant syndrome (NMS) was studied prospectively in two series of consecutive psychiatric in-patients (n = 223). The first group (n = 120) suffered from schizophrenia and was treated only with haloperidol. The second group (n = 103) was treated with diverse neuroleptics. All patients were on a single antipsychotic agent with no anticholinergic drug as prophylaxis. The incidence of full NMS per admission and first neuroleptic exposure was 5/223 (2.2%). Patients with bipolar affective disorder and those treated with injections were significantly over-represented in the NMS group.
Hermesh
H
H
Geha Psychiatric Hospital, Beilinson Medical Center, Petah Tikva, Israel.
Aizenberg
D
D
Weizman
A
A
Lapidot
M
M
Mayor
C
C
Munitz
H
H
D000284:Administration, Oral; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects; D006760:Hospitalization; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008728:Methotrimeprazine / Q000008:administration & dosage / Q000009:adverse effects; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000209:etiology*; D009460:Neurologic Examination / Q000187:drug effects; D010546:Perphenazine / Q000008:administration & dosage / Q000009:adverse effects; D011446:Prospective Studies; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; D008728:Methotrimeprazine; D003402:Creatine Kinase; D010546:Perphenazine; D006220:Haloperidol